Sol-Gel Technologies Ltd. (NASDAQ:SLGL) Forecasted to Post Q1 2025 Earnings of ($0.21) Per Share

Sol-Gel Technologies Ltd. (NASDAQ:SLGL) – Stock analysts at HC Wainwright issued their Q1 2025 earnings estimates for Sol-Gel Technologies in a research report issued on Monday, May 20th. HC Wainwright analyst R. Selvaraju forecasts that the company will post earnings per share of ($0.21) for the quarter. HC Wainwright has a “Buy” rating and a $6.00 price objective on the stock. The consensus estimate for Sol-Gel Technologies’ current full-year earnings is ($0.67) per share. HC Wainwright also issued estimates for Sol-Gel Technologies’ Q2 2025 earnings at ($0.21) EPS, Q3 2025 earnings at ($0.09) EPS and Q4 2025 earnings at ($0.10) EPS.

Sol-Gel Technologies Stock Down 1.2 %

Shares of SLGL opened at $0.79 on Tuesday. The company has a market capitalization of $22.01 million, a P/E ratio of -0.95 and a beta of 1.38. The firm has a 50 day moving average of $0.88 and a 200 day moving average of $1.10. Sol-Gel Technologies has a twelve month low of $0.63 and a twelve month high of $4.05.

Sol-Gel Technologies (NASDAQ:SLGL) last announced its earnings results on Wednesday, March 13th. The company reported ($0.17) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.01). The business had revenue of $0.45 million for the quarter, compared to the consensus estimate of $0.27 million. Sol-Gel Technologies had a negative net margin of 1,329.13% and a negative return on equity of 52.73%.

About Sol-Gel Technologies

Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc, develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea.